JS207
JS207 is a pharmaceutical drug with 10 clinical trials. Currently 9 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
3
Early Stage
7
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
9
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
JS212 Combination Therapies in Metastatic Colorectal Cancer
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC
Clinical Trials (10)
JS212 Combination Therapies in Metastatic Colorectal Cancer
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer
A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10